Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD2 | P06729 | 1/20 | 0.53 |
| ▸ | CD58 | P19256 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 10/20 | 0.45 |
| ▸ | MC5R | P33032 | 10/20 | 0.45 |
| ▸ | MC3R | P41968 | 10/20 | 0.45 |
| ▸ | MC1R | Q01726 | 10/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 3/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375812 | 0.97 | CD2 (0.54) | CD2CD58ERBB2MC4RMC5R | |
| SCHEMBL19367903 | 0.92 | ERBB2 (0.60) | CD2CD58ERBB2ITGB3ITGB1 | |
| SCHEMBL19375731 | 0.89 | ERBB2 (0.61) | CD2CD58ERBB2ITGB3ITGB1 | |
| SCHEMBL19367901 | 0.80 | ERBB2 (0.70) | ERBB2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL21766911 | 0.73 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL20888358 | 0.73 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL19605458 | 0.73 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL22970320 | 0.72 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12148757 | 0.72 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL24016804 | 0.72 | ITGB3 (0.53) | MC4RMC5RMC3RMC1RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963486-B2 | Peptidomimetics for treating HER2-overexpressed cancer | Board of Supervisors for the University of Louisiana System (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170267725-A1 | Peptidomimetics for Treating HER2-Overexpressed Cancer | Board of Supervisors for the University of Louisiana System (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267725-A1 | Peptidomimetics for Treating HER2-Overexpressed Cancer | ERBB2, EGFR, ERBB3 | CD2 3672/4885CD58 3079/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.